Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Receivables (2023 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Receivables for 4 consecutive years, with $80.7 million as the latest value for Q1 2026.

  • For Q1 2026, Receivables rose 121.99% year-over-year to $80.7 million; the TTM value through Mar 2026 reached $80.7 million, up 121.99%, while the annual FY2025 figure was $78.1 million, 101.38% up from the prior year.
  • Receivables hit $80.7 million in Q1 2026 for Phathom Pharmaceuticals, up from $78.1 million in the prior quarter.
  • Across five years, Receivables topped out at $80.7 million in Q1 2026 and bottomed at $1.6 million in Q4 2023.
  • Average Receivables over 4 years is $37.9 million, with a median of $37.6 million recorded in 2024.
  • Year-over-year, Receivables surged 2270.01% in 2024 and then skyrocketed 101.38% in 2025.
  • Phathom Pharmaceuticals' Receivables stood at $1.6 million in 2023, then soared by 2270.01% to $38.8 million in 2024, then surged by 101.38% to $78.1 million in 2025, then grew by 3.32% to $80.7 million in 2026.
  • According to Business Quant data, Receivables over the past three periods came in at $80.7 million, $78.1 million, and $55.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.